SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-016738
Filing Date
2022-11-08
Accepted
2022-11-08 07:30:38
Documents
73
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20220930x10q.htm   iXBRL 10-Q 1921288
2 EX-31.1 acrs-20220930xex31d1.htm EX-31.1 15600
3 EX-31.2 acrs-20220930xex31d2.htm EX-31.2 15620
4 EX-32.1 acrs-20220930xex32d1.htm EX-32.1 9437
  Complete submission text file 0001558370-22-016738.txt   8011203

Data Files

Seq Description Document Type Size
5 EX-101.SCH acrs-20220930.xsd EX-101.SCH 44196
6 EX-101.CAL acrs-20220930_cal.xml EX-101.CAL 51515
7 EX-101.DEF acrs-20220930_def.xml EX-101.DEF 214797
8 EX-101.LAB acrs-20220930_lab.xml EX-101.LAB 466067
9 EX-101.PRE acrs-20220930_pre.xml EX-101.PRE 336270
67 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20220930x10q_htm.xml XML 1601778
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 221367235
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences